Marius E. Kraenzlin, MD

Professor of Endocrinology

Date of birth
March 26, 1950

Missionsstraße 24
CH-4055 Basel/Switzerland
phone: +41 (0) 61 264 97 97
fax: +41 (0) 61 264 97 96
e-mail: Opens window for sending emailmarius.kraenzlin(at)

Academic appointments

1978 Dept. of Surgery, University Hospital Basel/CH
1979–1980 Dept. of Medicine, Kantonsspital Bruderholz/CH
1981 Psychiatric Clinic, University Basel/CH
1981–1982 Dept. of Medicine, University Hospital Basel/CH
1982–1983 Endocrine Unit (Senior House Officer), Dept. of Medicine, Hammersmith Hospital London/GB
1984 Royal Postgraduate Medical School (Research Fellow)/Endocrine Unit, Hammersmith Hosp. London/GB
1984–1986 Dept. of Medicine, Endocrine Unit (clinical and research registrar), University Hospital Basel/CH
1986–1988 Research Associate, Mineral Metabolism, Loma Linda University Loma Linda, California, USA

Present position

Endonet: Practice and Laboratory for Endocrinology, Diabetology and Metabolic Bone Disease, Basel/CH
Professor of Endocrinology Faculty of Medicine University of Basel
Consultant for Calcium and Bone Metabolism (since 1989)
Clinic for Endocrinology, Diabetology and Metabolism, University Hospital Basel, Basel/CH

Other professional activities


Swiss Association against Osteoporosis (SVGO): Committee member and secretary

1995–2001 Swiss Association against Osteoporosis (SVGO): President
1995–2001 Swiss Bone and Mineral Society (SBMS): Committee member

Swiss Society of Endocrinology and Diabetology (SGED): Committee member and secretary

2003– International Osteoporosis Foundation: Member of Committee Scientific Advisors
2003– International Society for Clinical Densitometry (ISCD): Member of "International Relation Committee"
2005– Deutsche Gesellschaft Osteologie (DGO): Committee member
2005– Member Ethic's Committee Basel (EKBB)
2005– International Osteoporosis Foundation: Leader of the IOF course in osteoporosis and densitometry certification
2009– Ethic's Committee Basel (EKBB): Vice-President
2011–2013 Deutsche Gesellschaft Osteologie (DGO): President
  • License and Board for Internal Medicine, Swiss Medical Association (FMH)
  • Board of Endocrinology and Metabolism, Swiss Medical Association (FMH)

Other memberships

  • Swiss Society of Internal Medicine (SGIM)
  • Swiss Society of Endocrinology and Diabetology (SGED)
  • American Society for Bone and Mineral Research (ASBMR)
  • International Bone and Mineral Society (IBMS)
  • European Calcified Tissue Society (ECTS)


  • Clinical research in metabolic bone disease, particulary osteoporosis
    - Diagnostic evaluation, treatment modalities a.o.
  • Evaluation and application of biochemical markers in metabolic bone disease
  • Pharmacoepidemiology related to osteoporosis

Selected recent publications:

Meier C, Kraenzlin ME, Bodmer M et al. Use of thiazolidinediones and fracture risk. Arch Intern Med 2008; 168: 820-825.

Kraenzlin M, Kraenzlin C, Meier C et al. Evaluation of an automated HPLC system for measurement of urinary collagen crosslinks: effect of age, menopause and metabolic bone diseases. Clin Chem 2008; 54: 1546-1553.

Meier C, Brauchli YB, Jick SS, Kraenzlin ME, Meier CR. Use of depot medroxyprogesterone acetate and fracture risk. J Clin Endocrinol Metab 2010; 95 (11): 4909–4916.

Maggio AB, Ferrari S, Kraenzlin M et al. Decreased bone turnover in children and adolescents with well controlled type 1 diabetes. J Pediatr Endocrinol Metab 2010; 23 (7): 697–707.

Kraenzlin ME, Graf C, Meier C et al. Beneficial effect of bisphosphonates in osteonecrosis of the knee. Knee Surgery, Sports Traumatology, Arthroscopy 2010; 18: 1638-1644.

Kraenzlin ME, Meier C. Parathyroid hormone analogues in the treatment of osteoporosis. Nature Rev Endocrinol 2011; 7: 647-656.

Sieber P, Lardelli P, Kraenzlin CA, Kraenzlin ME, Meier C. Intravenous Bisphosphonates for Postmenopausal Osteoporosis: Safety Profiles of Zoledronic Acid and Ibandronate in Clinical Practice Clin Drug Invest 2013; 33: 117-122.